Investors

Press Releases

Press Releases

Date	Title
November 24, 2020	Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference
November 18, 2020	Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™
November 16, 2020	Akebia Announces Manuscript Highlighting Global Phase 3 INNO2VATE Program Rationale, Study Design and Baseline Characteristics Published in Peer-Reviewed Medical Journal
November 5, 2020	Akebia Reports Third Quarter 2020 Financial Results and Recent Business Updates
November 3, 2020	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 26, 2020	Akebia Therapeutics to Report Third Quarter 2020 Financial Results and Discuss Recent Business Highlights
October 23, 2020	Akebia Presents Results from its PRO₂TECT Global Phase 3 Program of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients Not on Dialysis During Late-Breaking Session at American Society of Nephrology Kidney Week 2020 Reimagined
October 22, 2020	Akebia Presents Results from its INNO2VATE Global Phase 3 Program; Demonstrated Efficacy and Cardiovascular Safety of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
October 9, 2020	Akebia to Present Global Phase 3 Vadadustat Data at American Society of Nephrology Kidney Week 2020 Reimagined
October 2, 2020	Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Print Page

Email Page

Contact IR

Email Alerts

Tear Sheet

Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142

Driving Directions

+1 617.871.2098 phone
+1 617.871.2099 fax